RSPI (RespireRx Pharmaceuticals) Days Payable: 0.00 (As of Sep. 2023)

What is RespireRx Pharmaceuticals Days Payable?

RespireRx Pharmaceuticals RSPI 12 Days Payable is 0.00 as of Sep. 2023. GuruFocus rates RSPI with a GF Score™ of 12/100.

RespireRx Pharmaceuticals's average Accounts Payable for the three months ended in Sep. 2023 was $0.00 Mil. RespireRx Pharmaceuticals's Cost of Goods Sold for the three months ended in Sep. 2023 was $0.00 Mil.

The historical rank and industry rank for RespireRx Pharmaceuticals's Days Payable or its related term are showing as below:

RSPI's Days Payable is not ranked ^*
in the Biotechnology industry.
Industry Median: 112.84
* Ranked among companies with meaningful Days Payable only.

RespireRx Pharmaceuticals's Days Payable stayed the same from Sep. 2022 (0.00) to Sep. 2023 (0.00). stayed the same

RespireRx Pharmaceuticals Days Payable Related Terms

RespireRx Pharmaceuticals Days Payable Historical Data

* Premium members only.

The historical data trend for RespireRx Pharmaceuticals's Days Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

RespireRx Pharmaceuticals Days Payable Chart

RespireRx Pharmaceuticals Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Days Payable

Get a 7-Day Free Trial

0.00

RespireRx Pharmaceuticals Quarterly Data
	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23
Days Payable	Get a 7-Day Free Trial															0.00	0.00	0.00	0.00	0.00

RSPI vs CNBX, NAVB, IPIX: Days Payable Comparison

For the Biotechnology subindustry, RespireRx Pharmaceuticals's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

RespireRx Pharmaceuticals Days Payable vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, RespireRx Pharmaceuticals's Days Payable distribution charts can be found below:

* The bar in red indicates where RespireRx Pharmaceuticals's Days Payable falls into.

Save Embed

12GF Score

RespireRx Pharmaceuticals Inc RSPI

Days Payable is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

RespireRx Pharmaceuticals Days Payable Calculation

Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.

RespireRx Pharmaceuticals's Days Payable for the fiscal year that ended in Dec. 2022 is calculated as

	Days Payable (A: Dec. 2022 )
=	Average Accounts Payable					/	Cost of Goods Sold	*	Days in Period
=	( (Accounts Payable (A: Dec. 2021 )	+	Accounts Payable (A: Dec. 2022 ))	/	count )	/	Cost of Goods Sold (A: Dec. 2022 )	*	Days in Period
=	( (0	+	0)	/	1 )	/	0	*	365
=	0					/	0	*	365
=	N/A

RespireRx Pharmaceuticals's Days Payable for the quarter that ended in Sep. 2023 is calculated as:

	Days Payable (Q: Sep. 2023 )
=	Average Accounts Payable					/	Cost of Goods Sold	*	Days in Period
=	( (Accounts Payable (Q: Jun. 2023 )	+	Accounts Payable (Q: Sep. 2023 ))	/	count )	/	Cost of Goods Sold (Q: Sep. 2023 )	*	Days in Period
=	( (0	+	0)	/	1 )	/	0	*	365 / 4
=	0					/	0	*	365 / 4
=	N/A

Frequently Asked Questions Learn more about Days Payable →

What does a Days Payable of 0.00 mean?

RespireRx Pharmaceuticals (RSPI) has a Days Payable of 0.00 as of Sep. 2023. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on RespireRx Pharmaceuticals and its competitors.

Is RespireRx Pharmaceuticals' Days Payable too high?

RespireRx Pharmaceuticals' current Days Payable is 0.00. Overall, RespireRx Pharmaceuticals has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.

How does RespireRx Pharmaceuticals' Days Payable compare to CNBX and NAVB?

RespireRx Pharmaceuticals' Days Payable of 0.00 can be compared against companies in the Biotechnology industry. The industry median Days Payable is 112.84. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good Days Payable for a Biotechnology company?

The median Days Payable among Biotechnology companies is 112.84, based on 701 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high Days Payable mean?

A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on RespireRx Pharmaceuticals and its competitors. For the Biotechnology industry, the median Days Payable is 112.84 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. RespireRx Pharmaceuticals's current Days Payable is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is RespireRx Pharmaceuticals stock overvalued right now?

RespireRx Pharmaceuticals (RSPI) has a current Days Payable of 0.00. The current Days Payable is 0.00. RespireRx Pharmaceuticals' overall GF Score™ is 12/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is Days Payable calculated?

Days Payable is calculated from a company's financial statements. For RespireRx Pharmaceuticals (RSPI), the current Days Payable is 0.00 as of Sep. 2023. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

RespireRx Pharmaceuticals Business Description

Industry Healthcare Biotechnology

Comparable Companies CNBX NAVB IPIX PPCB ATRX PKBO EFTR ARDS NYMXF IVRN OCSE:NOVO B REGN VRTX ASX:CSL XKRX:207940 ALNY XBRU:UCB XKRX:068270 MRNA XBRU:ARGX

Address 126 Valley Road, Suite C, Glen Rock, NJ, USA, 07452

Website http://www.respirerx.com

RespireRx Pharmaceuticals Inc is engaged in the discovery, value-added development, and commercialization through partners of pharmaceuticals for the treatment of neurological and psychiatric disorders. The pipeline products of the company are dronabinol which is in a 505(b)(2) development ideas for the treatment of OSA (Obstructive Sleep Apnea), a form of sleep apnea; AMPAkines CX1739 for the treatment of bladder control and other conditions associated with spinal injury; CX717 for ADHD and CX1942 which is an injectable dosage formulation and GABAkines lead KRM-II-81 in preclinical development for treatment resistant epilepsy and non-opioid pain management.

12GF Score

Get the complete analysis for RSPI

Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.00

Price

View RSPI Analysis

See Days Payable data for all stocks →